ClinicalTrials.gg
CompletedNCT05183256Updated Jul 24, 2024

Cohort of Inflammatory Bowel Disease Patient in Yeouido St. Mary's Hospital

An observational study in Inflammatory Bowel Diseases, sponsored by Yeouido St. Mary's Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by Yeouido St. Mary's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of — 12 open to participants now, 15 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Korea, Republic of.

Enrollment
20th of 22
28 · median 240
Started
2020
with 5 others
Observational
22 of 57
7 open now
Registered
42nd of 57
by date

Among the 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 22 observational ones that give a count, is one of 6 that started in 2020, is one of 22 observational ones, and was the 42nd registered.

Inflammatory Bowel Diseases

1,553 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

12 of the 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 277 Inflammatory Bowel Diseases studies recruiting now, 134 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.

This study: Up to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The aim of this study is to analyze gut microbiota in IBD patients.

Read the detailed description

Inflammatory bowel disease (IBD) (Crohn's disease (CD) and ulcerative colitis (UC)) occurs worldwide with differences in epidemiology, etiology, and phenotype between regions. Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The DNA of microbiota will be investigated with samples of stool, colon tissue. The aim is to establish a cohort group for IBD (1), to make a database on cohort group characteristics such as endoscopic findings, disease severity, epidemiology, and prognosis (2), to analyze gut flora in IBD patients (3).

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients with IBD, presented to division of gastroenterology, Yeouido St.Mary's hospital, will be asked to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The below 3 conditions must be met simultaneously.

    1. Patient who can voluntarily consent to this study.
    2. Patient who has inflammatory bowel disease.
    3. Patient who is aged less than 75 years.

Exclusion criteria

Exclusion Criteria:

  • a patient meets any of the below conditions.

    1. If a patient has an IBD other than UC and CD.
    2. If a patient is vulnerable due to his/her position as an employee of Yeouido St.Mary's hospital or a medical student of the Catholic University of Korea.
    3. If a patient is pregnant.
    4. Foreign personal who cannot speak Korean.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Number of participants with the remission of disease activity.

    Disease activity is assessed in a clinical, endoscopic, and biochemical way. Each activity is determined by the Mayo score (in UC), Crohn's Disease Activity Index (in CD), Ulcerative Colitis Endoscopic Index of Severity (in UC), Simple Endoscopic Score for Crohn Disease (in CD), and biochemical findings (e.g. fecal calprotectin).

    Time frame: through study completion, an average of 2 year

07

Study locations

1 site
  • Yeouido St. Mary's hospital
    Seoul, 07241, Korea, Republic of
08

References and documents

Publications

  • Park SH, Kim YJ, Rhee KH, Kim YH, Hong SN, Kim KH, Seo SI, Cha JM, Park SY, Jeong SK, Lee JH, Park H, Kim JS, Im JP, Yoon H, Kim SH, Jang J, Kim JH, Suh SO, Kim YK, Ye BD, Yang SK; Songpa-Kangdong Inflammatory Bowel Disease [SK-IBD] Study Group. A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019 Oct 28;13(11):1410-1417. doi: 10.1093/ecco-jcc/jjz081. PubMed 30989166 ↗
  • Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest. 2014 Oct;124(10):4190-6. doi: 10.1172/JCI72330. Epub 2014 Aug 1. PubMed 25083986 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2023, 32 months.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 132. This study's 32 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Jan 10, 2022
StartActual
Oct 26, 2020
Primary completionActual
Jun 30, 2023
CompletionActual
Jul 24, 2023
Last update
Jul 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05183256
Lead sponsor
Yeouido St. Mary's Hospital
Responsible party
Ilsoo Kim, MD (Principal Investigator, Yeouido St. Mary's Hospital) — Principal investigator
First posted
Jan 10, 2022
Start date
Oct 26, 2020
Primary completion
Jun 30, 2023
Completion
Jul 24, 2023
Last update
Jul 24, 2024

Study contacts

Ilsoo Kim, MD
principal investigator · Yeouido St. Mary's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion